Kimura M, Tomita Y, Imai T, Saito T, Katagiri A, Ohara-Mikami Y, Matsudo T, Takahashi K
Division of Urology, Department of Regenerative and Transplant Medicine, Niigata University Graduate School of Medical and Dental Sciences, Niigata, Japan.
Cancer. 2001 Oct 15;92(8):2072-5. doi: 10.1002/1097-0142(20011015)92:8<2072::aid-cncr1547>3.0.co;2-p.
Evidence of systemic inflammation, i.e., elevation of serum C-reactive protein, interleukin-6, and/or the erythrocyte sedimentation rate, is correlated to poorer prognosis of patients with renal cell carcinoma (RCC). Serum amyloid A (SAA) has been recognized mainly as acute-phase reactant.
Serum SAA from 72 patients with RCC were examined. Thirty-eight of 72 patients with RCC had elevated SAA compared with 17 healthy donors.
The disease specific survival rate was significantly lower in the elevated SAA group, and SAA level was shown to be an independent prognostic factor by univariate and multivariate analysis.
Evaluation of serum SM level in RCC patients may be a useful prognostic indicator.
全身炎症的证据，即血清C反应蛋白、白细胞介素-6和/或红细胞沉降率升高，与肾细胞癌（RCC）患者的预后较差相关。血清淀粉样蛋白A（SAA）主要被认为是急性期反应物。
检测了72例RCC患者的血清SAA。72例RCC患者中有38例SAA升高，而17名健康供者中仅有17例升高。
SAA升高组的疾病特异性生存率显著较低，单因素和多因素分析显示SAA水平是一个独立的预后因素。
评估RCC患者的血清SAA水平可能是一个有用的预后指标。
